Meet Norway's oncology clinicians at ESMO 2026
23 October 2026 - 27 October 2026
Conference
Norway is coming to ESMO with a delegation of five leading oncology investigators from Oslo University Hospital, bringing expertise across key areas of cancer drug development.
If you are advancing oncology programmes and looking for experienced investigators and clinical trial sites in the Nordic region, this is an opportunity to meet the clinicians who could support your studies in Norway.
Tell us about your pipeline and we will arrange a one-to-one meeting with the relevant investigator during ESMO.
Meet the delegation
Our delegation brings together experienced oncology clinicians and investigators from Oslo University Hospital, Norway's largest hospital. Between them, they cover a broad range of cancer types and trial phases.
Åse Bratland
Head of Section, Head & Neck Oncology, Oslo University Hospital. PhD, Medical Oncologist
Oslo, Norway
Kristina Yvonne Lindemann
Head of Research, Department of Gynecological Oncology, Oslo University Hospital. Professor II, University of Oslo
The delegation brings together senior clinical and translational oncology leaders from Oslo University Hospital, covering:
- Gynaecological cancers
- Gastrointestinal cancers
- Thoracic oncology
- Head and neck cancers
- Immuno-oncology
- Biomarker-driven treatment
- Precision medicine
Together, the investigators bring experience across Phase I to III clinical trials, biomarker-driven and precision oncology studies, immunotherapy and targeted therapies, real-world evidence and registry-based research.
Could Norway support your clinical development programme?
One contract, multiple sites
Norway's clinical trial model allows one contract negotiation to cover several hospitals, reducing the need for separate site-by-site negotiations and helping simplify study start-up.
Visibility from contract to trial
A national clinical trials portal, launched in September 2026, gives sponsors, investigators and study leaders visibility into both contract negotiations and study progress.
Experienced investigators across oncology
Oslo University Hospital brings together clinicians and investigators working across major cancer indications and trial phases, with expertise spanning early-phase development through to late-stage studies.
Engage investigators early
Norway is working to increase the number of industry-sponsored clinical trials. Engaging investigators early can help companies assess site suitability, patient populations and study feasibility before programmes are finalised.
What are you developing?
We are particularly interested in meeting companies advancing:
Phase I to III trials
Biomarker-driven and precision oncology
Immuno-oncology and targeted therapies
Real-world evidence and registry-based research
Global multicentre studies expanding into the Nordic region
Bring your pipeline to Madrid
Tell us about your current or upcoming oncology programmes and we will connect you with the investigator whose expertise is most relevant.
Meet the Norwegian delegation at ESMO 2026.
Contact us
Questions about running your trial in Norway? Reach out to us directly.
Signe Øien Fretland
Head of NorTrials coordinating unit; Cand. Pharm.
Rasmus Malmborg
Investment Manager
Health and life science
Oslo
Jannik Grodt Schmidt
Investment Manager
Health and life science
New York, USA
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.